News for hackers. Stuff that matters.
Re:23andMe has signed a $300M deal with GlaxoSmithKline by aaavl2821 on Saturday January 05, 2019 @11:48AM (#18832600)
Recruiting patients for clinical studies can actually be quite hard, especially if you are looking only for patients with a specific mutation. Many companies now focus on studying genetically defined patient populations bc the signal to noise ratio is better. There is a massive shortage of patients for cancer studies now

As mentioned, 23andme uses genotyping not sequencing so it's unclear whether there data is that valuable for target discovery. and while it's not unprecedented for pharma to spend $300M for a target id deal, it is quite rare

There are no comments on this comment yet.